Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bll Invest S R L is currently prosecuting patents within the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action. This action is assigned to 1 distinct examiner, which minimizes the complexity of the prosecution process. Additionally, the work is situated within 1 distinct art unit, indicating that the company's current intellectual property efforts are concentrated in a specific area of biotechnological or pharmaceutical research.
KOROTCHKINA, LIOUBOV G is identified as the busiest examiner, currently overseeing 1 pending office action. Because the portfolio only has 1 distinct examiner, KOROTCHKINA, LIOUBOV G is responsible for the active office action responses. The presence of the workload within the 1 distinct art unit suggests a focused approach to securing patent rights. Legal counsel should focus on the specific examination style of KOROTCHKINA, LIOUBOV G to efficiently move the 1 pending office action toward a final disposition in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOROTCHKINA, LIOUBOV G | 1 | 29.5% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280926 | INACTIVATED STRAINS OF BACTERIA, SUCH AS VIABLE BUT NON-CULTURABLE BACTERIA, COMPOSITIONS AND USE THEREOF | KOROTCHKINA, LIOUBOV G | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280926 | INACTIVATED STRAINS OF BACTERIA, SUCH AS VIABLE BUT NON-CULTURABLE BACTERIA, COMPOSITIONS AND USE THEREOF | KOROTCHKINA, LIOUBOV G | 55d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280926 | INACTIVATED STRAINS OF BACTERIA, SUCH AS VIABLE BUT NON-CULTURABLE BACTERIA, COMPOSITIONS AND USE THEREOF | KOROTCHKINA, LIOUBOV G | 1653 | §103§112Other | Non-Final OA | 55d | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial